APA aipamena

Floc’h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Menard, L., . . . Cross, D. (2018). Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions. Mol Cancer Ther.

Chicago Style aipamena

Floc’h, Nicolas, et al. "Anti-tumor Activity of Osimertinib, an Irreversible Mutant-selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions." Mol Cancer Ther 2018.

MLA aipamena

Floc’h, Nicolas, et al. "Anti-tumor Activity of Osimertinib, an Irreversible Mutant-selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions." Mol Cancer Ther 2018.